Artal Group S.A. Xencor Inc Transaction History

Artal Group S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$20.69 - $37.79 $11.4 Million - $20.8 Million	-550,000 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$32.75 - $41.43 $8.19 Million - $10.4 Million	250,000 Added 83.33%	550,000 $18.9 Million
Q3 2019 Nov 14, 2019	BUY	$33.73 - $46.27 $843,249 - $1.16 Million	25,000 Added 9.09%	300,000 $10.1 Million
Q2 2019 Aug 09, 2019	SELL	$29.6 - $40.93 $6.66 Million - $9.21 Million	-225,000 Reduced 45.0%	275,000 $11.3 Million
Q3 2018 Nov 09, 2018	BUY	$35.69 - $47.65 $3.57 Million - $4.77 Million	100,000 Added 25.0%	500,000 $19.5 Million
Q2 2018 Aug 10, 2018	BUY	$28.41 - $42.41 $2.84 Million - $4.24 Million	100,000 Added 33.33%	400,000 $14.8 Million
Q1 2018 May 10, 2018	BUY	$21.18 - $33.78 $4.24 Million - $6.76 Million	200,000 Added 200.0%	300,000 $8.99 Million
Q3 2017 Nov 08, 2017	BUY	$19.61 - $23.35 $1.96 Million - $2.34 Million	100,000	100,000 $2.29 Million

216

71.8M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.49B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.